
Regulating Compounding in the GLP-1 Era: A Conversatio | Essential: The Pharmacy Compounding Podcast
About this episode
This episode we look at a bunch of statements from the FDA and from HHS Secretary Robert F. Kennedy, Jr. And of course there are peptides to talk about these days. Does anyone really know what’s going on with those? Our deep dive is a special one: Our guest is Al Carter, the CEO of the National Association of Boards of Pharmacy, and he gives us a totally different perspective on the regulatory landscape at the level that affects pharmacists every day. Links from the podcast: The latest FDA statement on DTE: https://fllw.me/4sL6zXw The Coalition for Compounding Excellence’s first audit process guide (compounding records and quality control): https://fllw.me/3Oew1qr FDA Law Blog on the state of peptide compounding: https://fllw.me/4cpFF2C National Association of Boards of Pharmacy: https://nabp.pharmacy Join APC! https://a4pc.org/join
Get every episode summarized
Each time Pharmacy Podcast Network publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Pharmacy Podcast Network

Thug Drugs: Psychedelic Studies | Pain Pod
Pharmacy Podcast Network

Beyond Dispensing: Building a Pharmacy Around Medication Management and Communit...
Pharmacy Podcast Network

More Patients, Same Pharmacists: Preparing Independent Pharmacy for the Next Era...
Pharmacy Podcast Network

Inventory, AI and Automation, R&D Tax Credits, Peptides, and Basis | The Bottom...
Pharmacy Podcast Network